MA30250B1 - Vaccins destines a lutter contre une infection a chlamydia - Google Patents

Vaccins destines a lutter contre une infection a chlamydia

Info

Publication number
MA30250B1
MA30250B1 MA30300A MA30300A MA30250B1 MA 30250 B1 MA30250 B1 MA 30250B1 MA 30300 A MA30300 A MA 30300A MA 30300 A MA30300 A MA 30300A MA 30250 B1 MA30250 B1 MA 30250B1
Authority
MA
Morocco
Prior art keywords
vaccines
chlamydia infection
proteins
polynucleotides
chlamydia
Prior art date
Application number
MA30300A
Other languages
English (en)
Inventor
Brenda Barth
Ajay Bhatia
Mark Alderson
Jean-Francois L Maisonneuve
Yves Lobet
Florence Bernadette Nozay
Martine Marchand
Pascal Mettens
Yasir A Skeiky
Peter Probst
Original Assignee
Glaxosmithkline Biolog Sa
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Corixa Corp filed Critical Glaxosmithkline Biolog Sa
Publication of MA30250B1 publication Critical patent/MA30250B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions comprenant des protéines ou des polynucléotides de Chlamydia sp., en particulier des combinaisons de protéines ou de polynucléotides codant ces compositions; et des méthodes d'utilisation des protéines ou des polynucléotides dans le traitement, la prévention et le diagnostic d'une infection à Chlamydia.
MA30300A 2005-03-31 2007-10-12 Vaccins destines a lutter contre une infection a chlamydia MA30250B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66733105P 2005-03-31 2005-03-31

Publications (1)

Publication Number Publication Date
MA30250B1 true MA30250B1 (fr) 2009-03-02

Family

ID=36646973

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30300A MA30250B1 (fr) 2005-03-31 2007-10-12 Vaccins destines a lutter contre une infection a chlamydia

Country Status (16)

Country Link
US (1) US20090022755A1 (fr)
EP (5) EP2386314A1 (fr)
JP (2) JP2008534594A (fr)
KR (1) KR20070121814A (fr)
CN (2) CN103372206A (fr)
AU (1) AU2006229968A1 (fr)
BR (1) BRPI0609547A2 (fr)
CA (1) CA2602637A1 (fr)
EA (2) EA201001322A1 (fr)
IL (1) IL186264A0 (fr)
MA (1) MA30250B1 (fr)
MX (1) MX2007012108A (fr)
NO (1) NO20075069L (fr)
SG (1) SG158145A1 (fr)
UA (1) UA97943C2 (fr)
WO (1) WO2006104890A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US20080213264A1 (en) * 1998-12-08 2008-09-04 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1891096A2 (fr) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Compositions immunogenes pour chlamydia trachomatis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
HRP20161606T1 (hr) 2007-03-02 2017-01-13 Glaxosmithkline Biologicals Sa Novi postupak i pripravci
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2413959A4 (fr) * 2009-01-29 2013-06-19 British Columbia Cancer Agency Compositions comportant des antigènes de chlamydia
IL208820A0 (en) * 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
CN103068837B (zh) 2010-05-28 2015-06-24 斯匹遐生物技术公司 嵌合momp抗原、方法和使用
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
KR101275263B1 (ko) * 2011-04-01 2013-06-14 서울대학교산학협력단 조류 병원성 대장균 특이 박테리오파지 및 이를 포함하는 항균 조성물
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections
EP2586789A1 (fr) * 2011-08-11 2013-05-01 InGen Biosciences Procédé pour le diagnostic d'infections Gram-négatives
EP2760468A4 (fr) * 2011-09-30 2015-08-12 Univ British Columbia Compositions d'antigène de chlamydia et leurs utilisations
US9827319B2 (en) 2012-05-29 2017-11-28 The Research Foundation For The State University Of New York Combined therapy and prophylaxis for genital tract infections
CA2881213A1 (fr) * 2012-08-08 2014-02-13 The University Of British Columbia Compositions antigeniques de chlamydia et leurs utilisations
CA2973220A1 (fr) 2014-01-16 2015-07-23 Mcmaster University Proteines injectisomes a secretion de type iii pour le traitement et la prevention d'infections chlamydiennes
EP3220962A4 (fr) * 2014-11-21 2018-07-25 Merck Sharp & Dohme Corp. Expression recombinante de l'antigène de momp de chlamydia
JP6952603B2 (ja) 2015-02-10 2021-10-20 オハイオ・ステイト・イノベーション・ファウンデーション クラミジア活性化ｂ細胞プラットフォーム及びその方法
JP7086000B2 (ja) 2015-11-10 2022-06-17 オハイオ・ステート・イノヴェーション・ファウンデーション 体液性親和性の加速に関する方法及び組成物
RU2676768C2 (ru) * 2016-05-12 2019-01-11 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Противохламидийная вакцина и способ ее получения
JP2020513836A (ja) * 2017-03-23 2020-05-21 オハイオ・ステイト・イノベーション・ファウンデーション 組換えクラミジア活性化ｂ細胞プラットフォーム及びその使用方法
CN108623657B (zh) * 2018-05-11 2021-02-12 苏州大学 多肽、重组dna分子、重组载体、外泌体及其应用
CA3209251A1 (fr) * 2021-01-29 2022-08-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides antigeniques de chlamydia trachomatis et leurs utilisations a des fins vaccinales
WO2025076039A1 (fr) * 2023-10-03 2025-04-10 The University Of North Carolina At Chapel Hill Facteur d'activité chlamydia de type protéase et compositions d'adjuvant et leurs utilisations
WO2025076210A1 (fr) * 2023-10-03 2025-04-10 Vaxcyte, Inc. Compositions de vaccin contre chlamydia

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811128A (en) 1986-10-24 1998-09-22 Southern Research Institute Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
WO1989001973A2 (fr) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ（ユーケー）リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
KR920007887B1 (ko) 1989-08-29 1992-09-18 스즈키 지도오샤 고오교오 가부시키가이샤 내연기관의 배기가스 정화장치
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
WO1991016116A1 (fr) 1990-04-23 1991-10-31 Cellpro Incorporated Dispositif et procede d'immunoselection
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
JP3040469B2 (ja) 1990-10-18 2000-05-15 セルプロ インコーポレイテッド 可撓性容器を用いて粒子を分離する装置及び方法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH07501687A (ja) 1991-08-15 1995-02-23 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） ボレリア・ブルグドルフェリのサブグループのｏｓｐ　ａ　蛋白、それをコードしている遺伝子およびワクチン
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
EP0678034B1 (fr) 1993-01-11 1999-05-26 Dana Farber Cancer Institute Procede permettant d'induire des reponses de lymphocytes-t cytotoxiques
FR2702160B1 (fr) 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
FR2704145B1 (fr) 1993-04-21 1995-07-21 Pasteur Institut Vecteur particulaire et composition pharmaceutique le contenant.
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
GB9506863D0 (en) * 1995-04-03 1995-05-24 Smithkline Beecham Biolog Vaccines
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU5972996A (en) 1995-06-02 1996-12-18 Incyte Pharmaceuticals, Inc. Improved method for obtaining full-length cdna sequences
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
KR100735651B1 (ko) 1997-11-28 2007-07-06 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PT1053325E (pt) 1998-02-05 2006-05-31 Glaxosmithkline Biolog Sa Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US7049302B1 (en) 1998-08-10 2006-05-23 Antigenics Inc. Compositions of CPG and saponin adjuvants and uses thereof
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6166177A (en) * 1998-12-08 2000-12-26 Corixa Corporation Compounds and methods for the treatment and diagnosis of chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
KR20100132086A (ko) * 1998-12-08 2010-12-16 코릭사 코포레이션 클라미디아 감염을 치료 및 진단하기 위한 조성물 및 이를 포함하는 약제학적 조성물 및 진단 키트
US6811783B1 (en) * 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
US20020146776A1 (en) * 2000-04-21 2002-10-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6919187B2 (en) * 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1278855B1 (fr) 2000-04-21 2008-03-12 Corixa Corporation Composes et procedes pour le traitement et le diagnostic d'une infection de chlamydia
US7537772B1 (en) * 2000-10-02 2009-05-26 Emergent Product Development Gaithersburg Inc. Chlamydia protein, gene sequence and the uses thereof
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002079244A2 (fr) * 2001-03-30 2002-10-10 University Of Manitoba Facteur d'activite a chlamydia du type protease responsable de la degradation du facteur de transcription de l'hote
US20030199438A1 (en) * 2001-04-09 2003-10-23 Shaw Allan Christian Method for identification of proteins from intracellular bacteria
US6770753B2 (en) * 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
CN100515494C (zh) * 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
CN1812809A (zh) * 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
US7892567B2 (en) * 2007-10-01 2011-02-22 Board Of Regents, The University Of Texas System Methods and compositions for immunization against chlamydial infection and disease

Also Published As

Publication number Publication date
EP2392347A3 (fr) 2012-01-18
JP2008534594A (ja) 2008-08-28
EA200701825A1 (ru) 2008-04-28
EA014527B1 (ru) 2010-12-30
NO20075069L (no) 2007-12-27
WO2006104890A2 (fr) 2006-10-05
MX2007012108A (es) 2007-12-05
CA2602637A1 (fr) 2006-10-05
EP2392347A2 (fr) 2011-12-07
AU2006229968A1 (en) 2006-10-05
CN101184504A (zh) 2008-05-21
EP2386314A1 (fr) 2011-11-16
BRPI0609547A2 (pt) 2011-10-18
EA201001322A1 (ru) 2011-02-28
EP2392348A2 (fr) 2011-12-07
EP2392348A3 (fr) 2012-01-18
IL186264A0 (en) 2008-01-20
SG158145A1 (en) 2010-01-29
CN103372206A (zh) 2013-10-30
EP2392349A2 (fr) 2011-12-07
JP2012180367A (ja) 2012-09-20
EP2392349A3 (fr) 2012-01-18
US20090022755A1 (en) 2009-01-22
EP1868641A2 (fr) 2007-12-26
WO2006104890A3 (fr) 2007-03-29
UA97943C2 (ru) 2012-04-10
KR20070121814A (ko) 2007-12-27

Similar Documents

Publication Publication Date Title
MA30250B1 (fr) Vaccins destines a lutter contre une infection a chlamydia
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MA34120B1 (fr) Composition pharmaceutique
BRPI0518249A2 (pt) plantas de algodço tolerantes À tensço
MA30343B1 (fr) Composition immunogene
CY1118006T1 (el) Χρηση γαλακτοβακιλλων για την αγωγη ιικων λοιμωξεων
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
EP2348035A3 (fr) Nouvelles compositions immunogènes pour la prévention et le traitement de la méningite à méningocoques
FR2894585B1 (fr) Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
WO2005102392A3 (fr) Methodes de traitement d'une infection a vih
ATE555814T1 (de) Radioaktive mittel für die in vivo pet-bildgebung von ccr5
EP2329838A3 (fr) Nétrine 4 mutée, ses fragments et leur utilisation comme médicaments
WO2006034001A3 (fr) Procedes de traitement de l'infection par vih
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
WO2005091937A3 (fr) Compositions utilisees dans le traitement d'infections microbiennes
ATE418613T1 (de) Antimikrobielle zusammensetzungen
WO2007030708A3 (fr) Adzymes antimicrobiens et leurs utilisations
EP1766391A4 (fr) Nouvelles methodes de diagnostic pour le traitement des infections par p. aeruginosa et reactifs pour ces methodes
WO2007075188A3 (fr) Procedes de traitement d'une infection a bacillus
WO2008001045A8 (fr) Membres de la famille de protéines connue sous le nom de famille des glycosides hydrolases 31
ATE420655T1 (de) Alpha-defensine als anthrax-immuntherapeutika